The health department plans to make the twice-a-year anti-HIV jab, lenacapavir, available at more than 300 government health districts with high HIV infection rates between April 2026 and March 2028.

CVS refused to cover Yeztugo, Gilead’s $28,000-a-year injectable PrEP, preventing patients from accessing the HIV prevention ...

All pharmacies are legally mandated to charge the state’s Medicaid program no more than the lowest price offered to other ...

A federal judge has recused herself from a criminal case involving a scheme to sell counterfeit HIV drugs on the black market ...

The oral antiviral obeldesivir reduces viral load in high-risk outpatients with COVID but does not lower the rate of ...

It’s up a good bit year to date, up like 28%. Still trades cheap. Very high quality company with a reasonable valuation.

The European Commission has formally approved a twice-yearly injection to prevent HIV, paving the way for its rollout across ...

The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV ...

AbbVie agreed to pay up to $1.2 billion to buy Gilgamesh Pharmaceuticals’ investigational psychedelic drug to treat major ...

The European Commission has granted marketing authorization for Yeytuo (lenacapavir)—Gilead Sciences Inc.’s twice-yearly ...

Gilead Sciences (GILD) stock in focus as its twice-yearly HIV PrEP therapy lenacapavir, is approved in the EU as Yeytuo for HIV prevention. Read more here.